MRI-PDFF

Biomarker1 paper

Latest

5

Frontiers in EndocrinologyReview16 Sep

Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis

SGLT2 inhibitors

Frontiers in GastroenterologyReview28 Aug

The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis

ADA Scientific Sessions 2026 AbstractHuman trial6 Jun

Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study

ADA Scientific Sessions 2026 AbstractHuman trial5 Jun

Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status

AHA Scientific Sessions 2025 AbstractHuman trial3 Nov

Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study

ADA Scientific Sessions 2025 AbstractHuman trial13 Jun

Effect of CT-388, a Signal-Biased Dual GLP-1/GIP Receptor Agonist, on Liver-Related MRI Parameters in Patients with Obesity